Agilus Diagnostics Expands Precision Diagnostics with Illumina NovaSeq X Installation in Mumbai

Designed for high-throughput sequencing at scale, the Illumina NovaSeq X supports rapid data generation with consistent accuracy, making it suitable for routine clinical decision-making.

Agilus Diagnostics, one of India’s largest diagnostic service providers and a subsidiary of Fortis Healthcare, has announced the commissioning of the Illumina NovaSeq X sequencing system at its Mumbai reference laboratory, marking a strategic step in scaling advanced molecular diagnostics.

Genomics has steadily moved from being a specialised research tool to becoming a cornerstone of modern healthcare. Over the past decade, next-generation sequencing has enabled clinicians to identify disease risk earlier, understand molecular drivers of complex conditions, and tailor treatment strategies with greater precision.

In India, demand for genomic testing has risen across oncology, rare and inherited disorders, reproductive health, pharmacogenomics, and infectious disease surveillance, driven by both clinical need and growing awareness of personalised medicine.

Designed for high-throughput sequencing at scale, the Illumina NovaSeq X supports rapid data generation with consistent accuracy, making it suitable for routine clinical decision-making rather than research alone. Through Agilus’ national laboratory network, these capabilities are positioned to reach clinicians and patients beyond major metropolitan centres, supporting wider access to precision diagnostics.

Operationally, the NovaSeq X uses high-density flow cells and advanced automation to enable whole exome sequencing, whole genome sequencing, and multi-omic analysis within defined clinical turnaround timelines.

This allows physicians to receive actionable molecular insights faster, an important factor when managing time-sensitive conditions such as cancer, inherited metabolic disorders, or complex infections.

Dr Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said, “Integrating advanced platforms like the Illumina NovaSeq X into clinical diagnostics is a pivotal step for India’s healthcare ecosystem. High-quality molecular insights are vital not only for oncology but also for diagnosing rare diseases, guiding targeted therapies, and advancing personalised and preventive care. Agilus’ investment brings cutting-edge science closer to patients and equips clinicians with actionable information to improve outcomes across a broad spectrum of conditions.”

Dr Anand K., Managing Director & CEO, Agilus Diagnostics, added, “The NovaSeq X marks a major step in our precision diagnostics journey. It strengthens our multi-omic capabilities across genomics and proteomics, enabling faster, high-resolution insights that power personalised medicine. This advancement brings us closer to delivering truly predictive and individualised care for patients across India.”

According to them, integrating these advanced assays into established clinical workflows allows complex genomic data to be translated into clear, clinically relevant reports.

The NovaSeq X installation aligns with Agilus Diagnostics’ longer-term focus on precision diagnostics and predictive healthcare, positioning the organisation to support future population genomics initiatives, proteomic programmes, and long-term patient monitoring while maintaining scale and nationwide accessibility.

Stay tuned for more such updates on Digital Health News